Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new windowYouTube page opens in new window
investorenquiries@pharmaust.com+61 3 9692 7222
PharmAust (PAA)
Cancer Therapeutics Research
PharmAust (PAA)
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT
  • HOME
  • ABOUT
    • Board
    • Management
    • Corporate Directory
  • PIPELINES & TRIALS
    • Monepantel for Motor Neurone Disease
    • Publications
  • INVESTOR HUB
    • ASX Announcements
    • Annual Reports
    • Investor Presentations
    • Analyst Reports
    • Financial Reports
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Videos
    • Media
  • CONTACT

Investor Presentations

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

PharmAust Roadshow Presentation

Investor Presentations 2023By PharmAust01/04/2023

PharmAust Roadshow Presentation

Read more

PharmAust Investor Webinar

Investor Presentations 2023By PharmAust01/03/2023

PharmAust Investor Webinar Presentation

Read more

AOG Energy Conference Presentation

Investor Presentations 2023By PharmAust01/03/2023

AOG Energy Conference Presentation

Read more

JP Equity Research Report

Investor Presentations 2022, News & Announcements 2022, Research Notes 2022By PharmAust22/07/2022

JP Equity Research Note – July 2022

Read more

Epichem OHD E-Waste Project – Feb 2022 Presentation to Department of Jobs, Tourism, Science and Innovation

Investor Presentations 2022By PharmAust16/02/2022

Epichem JTSI e-waste Presentation Final

Read more

Epichem Corporate Presentation July 2020

Investor Presentations 2020By PharmAust02/07/2020

Epichem Pty Ltd Corporate Presentation 2020 Final

Read more

PharmAust Shareholder Update Presentation June 2020

Investor Presentations 2020By PharmAust02/07/2020

PAA PRESENTATION JUN 2020 RA FINAL (1)

Read more

Pitt Street Research Life Science Conference: Investor Presentation

Investor Presentations 2019, News & Announcements 2019By PharmAust28/11/2019

191128_Investor Presentation

Read more

Investor Roadshow Presentation September 2019

Investor Presentations 2019, News & Announcements 2019By PharmAust09/09/2019

190909_Investor Roadshow Presentation September 2019

Read more

July 25 Investor Presentation

Investor Presentations 2019, News & Announcements 2019By PharmAust26/07/2019

190725_PAA PRESENTATION 25 JULY 2019

Read more

Investor Presentation (August)

31/08/2017

Investor Presentation (May)

10/05/2017

PharmAust AGM presentation

10/11/2016

PharmAust Investor Presentation – June 2016

10/08/2016

USA Roadshow Presentation – January 2016

15/01/2016

PharmAust AGM Presentation 2015

27/10/2015

EGM Shareholder Presentation

26/05/2015

PharmAust Shareholder Presentation – March 2015

15/03/2015
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

PharmAust Follow

PharmAust is a clinical-stage biotech company focused on repurposing monepantel (MPL) for human neurodegenerative diseases ASX: $PAA FSE: $ECQ

PharmAust
pharmaust PharmAust @pharmaust ·
8 Oct

💰 PharmAust (ASX: PAA) secures an $887K rebate under Australia’s R&D Tax Incentive, boosting resources for our ALS research and monepantel development! Further rebate expected soon to support our Phase 2/3 trials. #Biotech #ALSResearch #PharmAust

Reply on Twitter 1843778269679890469 Retweet on Twitter 1843778269679890469 2 Like on Twitter 1843778269679890469 6 Twitter 1843778269679890469
Retweet on Twitter PharmAust Retweeted
stockheadau Stockhead @stockheadau ·
17 Sep

PharmAust has submitted a request for orphan medicinal product designation to the European Medicines Agency for its lead drug monepantel for the treatment of amyotrophic lateral sclerosis (ALS). @PharmAust #ASX $PAA

Reply on Twitter 1836188877763084695 Retweet on Twitter 1836188877763084695 1 Like on Twitter 1836188877763084695 7 Twitter 1836188877763084695
pharmaust PharmAust @pharmaust ·
17 Sep

📎PharmAust submits Orphan Medicinal Product Designation request to EMA for monepantel, targeting ALS! If granted, this would provide regulatory support & 10 years of EU market exclusivity. Decision expected in Dec 2024. Exciting times ahead! 🌍 #PharmAust #Biotech #ALS

Reply on Twitter 1835861750488711336 Retweet on Twitter 1835861750488711336 1 Like on Twitter 1835861750488711336 7 Twitter 1835861750488711336
Load More

Copyright © 2024 PharmAust. All rights reserved.
nil

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top